Skip to content

Preemptive Analgesic Efficacy of Intramuscular Parecoxib Sodium versus Ketorolac for Third Molar Surgical Removal

Preemptive Analgesic Efficacy of Intramuscular Parecoxib Sodium versus Ketorolac for Third Molar Surgical Removal

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
TCTR
Registry ID
TCTR20250619002
Enrollment
28
Registered
2025-06-19
Start date
2024-06-03
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients requiring surgical removal of bilateral lower third molars with moderate to high levels of difficulty. Preemptive analgesia, Third molar surgical removal, Pain, Parecoxib, Ketorolac

Interventions

intramuscular parecoxib 20 mg, participants will receive a medication injection in the deltoid muscle 15 minutes before the surgery. ,intramuscular ketorolac 30 mg, participants will receive a medicat
Experimental Drug,Active Comparator Drug
Parecoxib,Ketorolac

Sponsors

Faculty of Dentistry, Prince of Songkla University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 30 Years

Inclusion criteria

Inclusion criteria: 1. ASA Classification I, II, 2. Thai patient, 3. Patients who require lower third molar surgery on both sides, 4. No sign of infection or pericoronitis, 5. Impacted tooth difficulty level of Pedersons difficulty index 5-10 points, 6. Patients should have the same Pederson's difficulty level on both sides 7. BMI 18.5-29.9 kg/m2 and weight 40-80 kg.

Exclusion criteria

Exclusion criteria: 1. Anaphylactic reaction/hypersensitivity to Parecoxib, Ketolorac, acetylsalicylic acid (aspirin), or NSAIDs, including other COX-2 specific inhibitors., 2. Patients with asthma, poisoning, or allergic reactions after taking aspirin or non-steroidal anti-inflammatory drugs (NSAIDs), including other non-selective COX-2 inhibiting anti-inflammatory drugs., 3. Patients who receive analgesic drugs before the operation not more than 6 hours, 4. Patients with active peptic ulceration or gastrointestinal bleeding, 5. Patients with a history of heart disease, 6. Pregnant women or breastfeeding mothers, 7. Patients with existing gastric ulcers or gastrointestinal bleeding, 8. Patients with inflammatory bowel disease,9. Patients who receive anticoagulants such as Warfarin, Heparin, and, antiplatelet drugs, or steroids, 10. Patients with a history of kidney disease, 11. Patients with blood clotting and coagulation disorders, 12. Individuals using other pain-relieving medications such as TCAs, Gabapentinoids, or Cannabis, 13. Alcohol consumers, 14. Heavy smokers (smoking more than 10 cigarettes per day)

Design outcomes

Primary

MeasureTime frame
Pain intensity 2, 4, 6, 8, 10, 12, and 24 hours after operation Visual Analog Scale ,Amount of rescue medication 24 hours after operation number of tablets,Time to first rescue medication 24 hours after operation minutes

Secondary

MeasureTime frame
Mouth opening distance Baseline, postoperative day 1, post operative day 7 millimeters,Facial swelling Baseline, postoperative day 1, post operative day 7 millimeters

Countries

Thailand

Contacts

Public ContactSurapong Vongvatcharanon

Faculty of Dentistry, Prince of Songkla University

surapong7503@gmail.com0818215091

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 10, 2026